Search results | biomarker

Reports

Biomarker Partnering Terms & Agreements

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Monoclonal Antibodies Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.

Personalized Medicine Partnering Terms & Agreements

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. 

Insights

Biomarker

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use

Biomarkers: recent life science industry trends

Recent advances in biomarkers, pharmacogenomics, bioinformatics and companion diagnostics have raised opportunities in the emerging field of personalized medicine

NIH Alzheimer’s initiative to fund small business biomarker studies

As part of a plan to inject $50 million into Alzheimer’s disease studies announced last month, the National Institutes of Health will fund new research by small businesses that seek to discover disease and drug-related biomarkers. 

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

InterMune looking for oppurtunities for buyout

Multiple sources are reporting that biotechnology company, InterMune, Inc. (ITMN), is officially preparing for a buyout.

Oncology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in oncology partnering with an increase in modern diagnostic technologies, according to recent partnering deals analysis

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Personalized medicine

Personalized medicine proposes customization of healthcare – with medical decisions, practices, and/or…

Pharmacogenomics

Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by…

Events

Sorry, your search returned no results.


Deals

Collaboration and licensing agreement for genomic-based diagnostic biomarker

NuView Life Sciences announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical to further develop and commercialize NuView’s investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate.

Banyan Biomarkers signs pharma licensing deal with Abbott

Banyan Biomarkers has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott for assessment and verification . The terms of the in a pharma licensing agreement were not disclosed.

Licensing agreement for biomarker SF3B1

QIAGEN sees potential for developing companion diagnostics to guide treatment with new anti-cancer compounds under development that target QIAGEN announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo.

Qiagen and Eli Lilly sign a biotech deal for biomarkers

QIAGEN announced a collaboration on a biotech deal with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.

Collaboration agreement to initiate multi-center idiopathic pulmonary fibrosis registry and biomarker bank

Boehringer Ingelheim Pharmaceuticals and Duke Clinical Research Institute have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis.

Collaboration agreement for validating colorectal biomarker

IntegraGen announced a collaboration with investigators from the New EPOC study to validate the oncology biomarker hsamiR313p.

KineMed biopharma partners with Amgen for kinetic biomarkers

KineMed biopharma partners with Amgen, a big pharma company, to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases

Joslin pharma partnering with Eli Lilly and Pfizer for biomarkers

Joslin Diabetes Center’s Office of Commercialization and Ventures is pharma partnering with Eli Lilly and Company and Pfizer which will enable Joslin and both companies to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes and developing potential ways to treat and prevent this complication of diabetes

Biogen Idec big pharma deals Adaptive Biotechnologies for immunological biomarkers collaborative R&D

Adaptive Biotechnologies signed pharma deals with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases.

BMS pharma deals for oncology biomarkers in collaborative R&D with Adaptive biotechnologies

Bristol-Myers Squibb has entered into a collaborative R&D pharma deals agreement with Adaptive biotechnologies  for the discovery of immunological biomarkers in oncology.